Skip to main content

Agitation Associated with Dementia Due to Alzheimer’s Disease News

Alzheimer’s Drug, Leqembi, Can Be Safely Administered In Memory Clinics, Study Says

THURSDAY, May 15, 2025 — The 2023 approval of the first drug shown to slow the progression of Alzheimer’s disease came with no small amount of concern from skeptics. Lecanemab (Leqembi) modestly slo...

Alzheimer’s Drug, Leqembi, Can Be Safely Administered In Memory Clinics, Study Says

THURSDAY, May 15, 2025 — The 2023 approval of the first drug shown to slow the progression of Alzheimer’s disease came with no small amount of concern from skeptics. Lecanemab (Leqembi) modestly slo...

Portable AI System Can Help Detect Brain Decline

FRIDAY, March 21, 2025 – A portable system powered by artificial intelligence (AI) can help detect early signs of brain decline, potentially offering up a red flag for people at risk of dementia or...

Burden of Alzheimer Disease Rose Worldwide From 1990 to 2021

THURSDAY, March 20, 2025 – The burden of Alzheimer disease and other dementias (ADODs) rose globally from 1990 to 2021, according to a study published online in the April issue of the American...

Money, Education Helps Determine Your Odds for Dementia

FRIDAY, Nov. 1, 2024 – Folks with more money and better education are at less risk for developing dementia as they grow older, a new study shows. People with advantaged backgrounds are less likely...

Otsuka and Lundbeck Announce U.S. FDA Approval of Supplemental New Drug Application (sNDA) for Rexulti (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease

PRINCETON, NJ and DEERFIELD, IL – May 10, 2023 – Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Lundbeck LLC (Lundbeck) announce the U.S. Food and Drug Administration (FDA) has approved the sup...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Alzheimer's Disease

Related drug support groups

Rexulti